Historical Aspects of Transcatheter Occlusion of Atrial Septal Defects

Alapati, Srilatha; Rao, P. Syamasundar

doi:10.5772/38930

Cited by 10 publications

(15 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twelve (63%) of 19 had no residual shunts on echocardiographic studies during follow-up [ 28 ]. Studies by these and other cardiologists, as reviewed elsewhere [ 14 ] were conducted. But, several investigators [ 29 , 30 , 31 ] detected fractures in the arms of the clamshell occluder in 40% to 84% of the patients with infrequent embolization [ 29 , 30 , 31 ].…”

Section: Discontinued Devicesmentioning

confidence: 99%

“…There are a number of devices which have not received approval by the FDA for unrestricted clinical application namely, modified Rashkind PDA umbrella device, CardioSEAL device, STARFlex device, Sideris’ wireless devices (including trans-catheter patch), hybrid buttoned device, BioSTAR, BioTREK, Occlutech, Cardia devices (ATRIASEPT I-ASD device, ATRIASEPT II-ASD and ULTRASEPT), Solysafe Septal Occluder device and PFM ASD-R device. Discussion of these devices is beyond the scope of this presentation but the information pertaining to these devices is briefly reviewed elsewhere [ 14 ] for the interested reader.…”

Section: Devices Not Yet Approved By Fdamentioning

confidence: 99%

“…As a result, extensive attempts were undertaken by cardiologists around the world to develop a percutaneous method without surgery for ASD closure. Since the initial reports in the mid-1970s by King [ 6 , 7 , 8 ], Rashkind [ 9 , 10 , 11 ] and their associates of ASD occluding devices, several types of devices, as appraised in the author’s prior publications [ 12 , 13 , 14 ], have emerged. Accordingly, two methods, namely, surgical and transcatheter closure, are now available for ASD occlusion.…”

Section: Introductionmentioning

confidence: 99%

“…Despite the description of many different devices [ 12 , 13 , 14 ], only four devices, namely, the Amplatzer Septal Occluder (ASO) (St. Jude Medical, Inc., St. Paul, MN, USA—Abbott), Amplatzer Cribriform Device (St. Jude Medical, Inc.), Gore HELEX ® Device (W.L. Gore, Flagstaff, AZ, USA) and GORE ® CARDIOFORM ASD Occluder (W.L.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Outcomes of Device Closure of Atrial Septal Defects

Rao

2020

Children

View full text Add to dashboard Cite

Several devices have been designed and tried over the years to percutaneously close atrial septal defects (ASDs). Most of the devices were first experimented in animal models with subsequent clinical testing in human subjects. Some devices were discontinued or withdrawn from further clinical use for varied reasons and other devices received Food and Drug Administration (FDA) approval with consequent continued usage. The outcomes of both discontinued and currently used devices was presented in some detail. The results of device implantation are generally good when appropriate care and precautions are undertaken. At this time, Amplatzer Septal Occluder is most frequently utilized device for occlusion of secundum ASD around the world.

show abstract

Section: Discontinued Devicesmentioning

confidence: 99%

Section: Devices Not Yet Approved By Fdamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Outcomes of Device Closure of Atrial Septal Defects

Rao

2020

Children

View full text Add to dashboard Cite

show abstract

“…A number of other devices are in clinical trials either in the US or in other countries. The interested reader referred elsewhere [7,[174][175][176] for a more detailed discussion of historical aspects of ASD closure devices.…”

Section: Atrial Septal Defectmentioning

confidence: 99%

Historical Aspects of Transcatheter Treatment of Heart Disease in Children

Rao¹

2012

Pediat Therapeut

View full text Add to dashboard Cite

The very first transcatheter intervention to treat congenital cardiac defects was reported by Rubio-Alvarez et al. [1] in 1953, when they performed pulmonary valvotomy using a modified ureteral catheter. A decade later Dotter, Rashkind, Porstmann and their associates described progressive dilatation of peripheral arterial stenotic lesions, balloon atrial septostomy and transcatheter occlusion of patent ductus arteriosus, respectively. The purpose of this review is to present these and other historical developments of catheter-based interventions in the treatment of heart disease in children. Historical aspects of 1. balloon angioplasty/valvuloplasty of valvar pulmonary stenosis, valvar aortic stenosis, fixed subaortic stenosis, native aortic coarctation, postsurgical aortic recoarctation, branch pulmonary artery stenosis, mitral stenosis, cyanotic heart defects with pulmonary oligemia, stenotic bioprosthetic valves, congenital tricuspid and mitral stenosis, truncal valve stenosis, subvalvar pulmonary stenosis, supravalvar pulmonary stenosis (congenital membranous or postoperative), stenosis of the aorta (Leriche syndrome, atherosclerotic and Takayasu's arteritis), baffle obstruction following Mustard or Senning procedure (both systemic and pulmonary venous obstructions), superior and inferior vena caval obstructions, pulmonary vein stenosis, pulmonary veno-occlusive disease, vertical vein stenosis in total anomalous pulmonary venous connection, pulmonary venous obstruction following repair of total anomalous pulmonary venous obstruction, specially designed pulmonary artery bands, cor triatriatum, cor triatriatum dexter, and coronary artery stenotic lesions that develop after Kawasaki disease; 2. stents to enlarge stenotic lesions of branch pulmonary arteries, systemic veins, systemic and pulmonary venous pathways after Mustard procedure, aorta, right ventricular outflow conduits, pulmonary veins and native right ventricular outflow tract or to keep the ductus arteriosus open in patients with pulmonary atresia and hypoplastic left heart syndrome and maintaining patency of stenosed aorto-pulmonary collateral vessels, surgically created but obstructed shunts or acutely thrombosed shunts as well as covered stents; 3. transcatheter occlusion of cardiac defects comprising of atrial septal defect, patent foramen ovale, patent ductus arteriosus, ventricular septal defect and aortopulmonary window and 4. catheter-based atrial septostomy such as Rashkind balloon atrial septostomy, Park's blade atrial septostomy, balloon angioplasty of the atrial septum, trans-septal puncture and atrial septal stents were presented.

show abstract

Cocoon devices for transcatheter closure of atrial septal defect and patent ductus arteriosus in children

et al. 2019

View full text Add to dashboard Cite

Closure of the atrial septal defect (ASD) and patent ductus arteriosus (PDA) are among the most frequent cardiac interventional procedures. This was a prospective study, which started together with the implementation of a national program of pediatric interventional cardiology in Romania. We used Cocoon devices in 83 consecutive cases from 92 implantations for ASD and PDA. 27 cases were ASD closure and 56 cases PDA closure. Regarding the ASD closure, the median age was 8.5 years (range 3–25 years) and median weight 25 kg (range 11.5–63 kg). The mean follow-up was 17.4 ± 6.7 months (range 3–26 months). The mean ASD diameter by transesophageal echocardiography was 15.2 ± 4.1 mm (range 8–26 mm). The mean device diameter used was 17.3 ± 5.6 mm (range 8–32 mm). Regarding the PDA closure, the median age was 36 months (range 4–192 months) and median weight 14 kg (range 5–58 kg). The mean follow-up was 15 ± 8 months (range 3–28 months). The mean PDA minimum diameter was 2.5 ± 0.8 mm. The success implantation rate for both groups was 97.6% (2 cases of withdrawn for ASD and PDA), while the complication rate was 2.3% (including 2 ASD device embolization). In the first 24 hours, the closure rates were 96.3% for ASD, 98.2% for PDA, and 100% at 1-month follow-up for both procedures. On short and intermediate follow-up (3–28 months), no device-related complications were noted.The Cocoon devices are safe for transcatheter closure of both ASD and PDA, and the initial experience with their use in our emerging center is encouraging.

show abstract

Historical Aspects of Transcatheter Occlusion of Atrial Septal Defects

Cited by 10 publications

References 70 publications

Outcomes of Device Closure of Atrial Septal Defects

Outcomes of Device Closure of Atrial Septal Defects

Historical Aspects of Transcatheter Treatment of Heart Disease in Children

Cocoon devices for transcatheter closure of atrial septal defect and patent ductus arteriosus in children

Contact Info

Product

Resources

About